Liquidia reached a $380.7 million settlement with United Therapeutics, resolving six lawsuits over Yutrepia and ending a years-long legal battle. Liquidia will pay an initial $175 million alongside installment payments through 2027 while relinquishing its PH-ILD indication and withdrawing FDA labeling. Liquidia retains rights to market Yutrepia for PAH, prompting a 26% to 37% surge in Liquidia shares following the announcement.
Settlement payment terms and funding
- ▪Liquidia Chief Financial Officer Michael Kaseta stated Liquidia plans to fund the $380.7 million settlement using ongoing Yutrepia sales and its $396.1 million in cash reserves held as of September 30, 2026.
- ▪Liquidia scheduled a $60.3 million payment in October 2026 to resolve related antitrust litigation concerning Treprostinil Injection.
- ▪Liquidia agreed to pay approximately $380.7 million in total settlement costs to United Therapeutics and other parties in installments extending through 2027.
- ▪Liquidia will make an initial net payment of $175 million to United Therapeutics within 30 business days, followed by two installments of $72.7 million on January 31 and April 30, 2027.
Resolution of pending lawsuits
- ▪The October 13, 2026 settlement resolves six pending lawsuits between Liquidia and United Therapeutics covering patent infringement, trade secrets, contracts, and antitrust claims regarding treprostinil treatments.
- ▪The settlement between Liquidia and United Therapeutics contains mutual legal releases without liability admissions and requires filing for formal dismissal of all pending litigation with prejudice.
Yutrepia marketing restrictions and permissions
- ▪Liquidia agreed to work immediately with the U.S. Food and Drug Administration to remove the indication for pulmonary hypertension associated with interstitial lung disease (PH-ILD) from Yutrepia's prescribing label.
- ▪Liquidia agreed to stop promoting, detailing, and commercializing Yutrepia for PH-ILD, terminate trial cohorts studying PH-ILD, and cease publication of related clinical data.
- ▪The settlement agreement permits Liquidia to continue commercializing, detailing, and selling Yutrepia for pulmonary arterial hypertension (PAH).
Stock market reaction to settlement
- ▪Liquidia shares rose 26% to 37.6% on October 14, 2026 following the settlement announcement, after having lost over half their value following the September 30, 2026 adverse Delaware court ruling.
- ▪United Therapeutics shares fell nearly 0.6% to 1% in morning trading on October 14, 2026 following the announcement of the $381 million settlement.
District court ruling and appeal
- ▪On September 30, 2026, the U.S. District Court for the District of Delaware ruled that Liquidia infringed two valid claims of United Therapeutics' U.S. Patent No. 11,826,327 covering inhaled treprostinil methods for PH-ILD.
- ▪Liquidia agreed not to appeal the U.S. District Court for the District of Delaware's September 30, 2026 patent infringement ruling as part of the overall settlement.
Liquidia business strategy and pipeline
- ▪Liquidia Chief Executive Officer Roger Jeffs stated on October 14, 2026, that Liquidia will focus its resources on making Yutrepia the prostacyclin therapy of choice in PAH.
- ▪Liquidia reported preliminary third-quarter 2026 Yutrepia net product sales of $222.7 million while continuing development of its next-generation liposomal treprostinil candidate L606 for PAH and PH-ILD.
Story comments
Loading comments…